CytomX Therapeutics CTMX shares surged 5.13% following high-impact J.P. Morgan Healthcare Conference presentation

CytomX Therapeutics (CTMX) shares surged 5.13% in pre-market trading on January 15, 2026, following a high-impact presentation at the 44th Annual J.P. Morgan Healthcare Conference. The rally reflects renewed investor confidence in the biotech firm’s oncology pipeline advancements.

During the session, CEO Sean McCarthy highlighted progress across key programs. Varsetatug masetecan, the company’s lead EpCAM-targeting PROBODY® ADC for colorectal cancer, is advancing into later-line trials with Phase 1 expansion data expected in Q1 2026. The asset’s potential to address a large patient population—given consistent EpCAM expression across CRC stages—was emphasized as a strategic differentiator.

CX-801, a PROBODY® interferon therapy for melanoma, showed early immune activation signals in monotherapy and is set to report combination data with KEYTRUDA by year-end. The company also outlined plans to expand Varsetatug into earlier-line CRC and additional EpCAM-positive indications by mid-2026, supported by its proprietary platform for masked therapeutics.

With cash runway extending through Q2 2027 and partnerships with industry leaders like Bristol Myers Squibb and Amgen, CytomX’s focus on unmet needs in oncology—particularly high-mortality cancers like metastatic colorectal disease—positions it to capitalize on a $3.8 billion ADC market opportunity. The presentation underscored a disciplined approach to pipeline development, balancing innovation with commercial viability.